Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
LiquidLink startet Bitcoin Lightning- und XRP-ILP-Nodes - Aufbau des Rückgrats der tokenisierten Finanzwelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
271 Leser
Artikel bewerten:
(1)

ACDM Honors PHASTAR with Award for Innovation in the Management of Clinical Trial Data

DURHAM, NC and LONDON, UK / ACCESSWIRE / September 22, 2021 / PHASTAR, a global specialist biometrics contract research organization (CRO) offering industry leading data management, data science, statistical consulting and clinical trial reporting services, was announced as a joint winner of the 2021 Innovation in the Management of Clinical Data Award by the Association for Clinical Data Management (ACDM).

The award was in recognition of the work done by PHASTAR data scientists and data managers to develop a novel AI and rule-based approach for the production of auto-generated queries used to identify potential data issues and inconsistencies in clinical trial data. The PHASTAR team integrated the role of the human expert with intelligent process automation through a targeted approach. They are able to discover hotspots of data quality issues on studies through the application of AI (NLP) approaches to the meta data, identifying problematic forms and variables and are now building labelled data sets to which machine learning methods may be applied.

"It is truly a honor to be recognized by our industry peers for the outstanding contributions PHASTAR data science and data management teams have made to assure more accurate outcomes in clinical trials," said Andrew MacGarvey, Chief Executive Officer, PHASTAR. "Data quality is an important pillar in the successful collection of clinical data. By creating innovative approaches, the application of advanced technologies like AI and Machine Learning will continue to impact the success of drug discovery and development."

The Association for Clinical Data Management (ACDM) represents professionals working in the management of clinical data. Founded over 30 years ago, they have been at the forefront of changes in all aspects of the management of clinical data in clinical trials and support their members through training, conferences, discussions and information provision. ACDM represents and supports professionals involved with managing, capturing, handling and designing methods to collect clinical data from within the pharmaceutical, biotechnology and academic research fields.

About PHASTAR

PHASTAR is a global specialist biometrics contract research organization offering industry leading data management, data science, statistical consulting, and clinical trial reporting services by providing expert consultants and managing and delivering in-house projects, FSP style arrangements and preferred partnerships. PHASTAR currently has over staff across 14 offices (United States, United Kingdom, Australia, Germany, Kenya, Japan, India and China) with plans to open additional locations in the future to serve prospective and existing clients. PHASTAR's number one priority is to ensure that the work produced is of the highest quality. Every project PHASTAR undertakes utilizes unique internal processes which are designed to ensure optimal quality.

All PHASTAR's data management, data science statistical and programming, staff are trained in the "PHASTAR Discipline" - an in-house approach to data analysis and collection. This comprises a set of common sense (but commonly ignored) principles that, if followed, guarantee error free outcomes. The "PHASTAR Discipline" also includes a series of intranet-based checklists highlighting potential pitfalls and points-to-consider when conducting clinical trials, enabling over 4,000 years of combined technical knowledge to be shared across the company.

For further information on PHASTAR contact tellmemore@phastar.com.

U.S. Media Contact

Dawn Fontaine
Ripple Effect Communications
617-536-8887
dawn@rippleeffectpr.com

SOURCE: PHASTAR



View source version on accesswire.com:
https://www.accesswire.com/665168/ACDM-Honors-PHASTAR-with-Award-for-Innovation-in-the-Management-of-Clinical-Trial-Data

© 2021 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.